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Fused deposition modelling (FDM) is the most commonly investigated 3D printing 
technology for the manufacture of personalized medicines, however, high temperatures 
associated with the process limit its wider application. The objective of this study was to print 
low-melting and thermolabile drugs by reducing the FDM printing temperature. Two 
immediate release polymers, Kollidon VA64 and Kollidon 12PF were investigated as 
potential candidates for low-temperature FDM printing. Ramipril was used as the model low 
melting temperature drug (109°C); to the authors’ knowledge this is the lowest melting point 
drug investigated to date by FDM printing. Filaments loaded with 3% drug were obtained by 
hot melt extrusion at 70°C and ramipril printlets with a dose equivalent of 8.9 mg were 
printed at 90°C. HPLC analysis confirmed that the drug was stable with no signs of 
degradation and dissolution studies revealed that drug release from the printlets reached 
100% within 20 to 30 mins. Variable temperature Raman and solid state nuclear magnetic 
resonance (SSNMR) spectroscopy techniques were used to evaluate drug stability over the 
processing temperature range. These data indicated that ramipril did not undergo degradation 
below its melting point (which is above the processing temperature range: 70-90 °C) but it 
was transformed into the impurity diketopiperazine upon exposure to temperatures higher 
than its melting point. The use of the excipients Kollidon VA64 and Kollidon 12PF in FDM 
was further validated by printing with the drug 4-aminosalicylic acid (4-ASA), which in 
previous work was reported to undergo degradation in FDM printing, but here it was found to 
be stable. This work demonstrates that the selection and use of new excipients can overcome 
one of the major disadvantages in FDM printing, drug degradation due thermal heating, 
making this technology suitable for drugs with lower melting temperatures.  
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3D printing techniques have come a long way since their inception in the early ‘90s, when 
they were developed for rapid and economic production of prototype models (Sachs et al., 
1993), to their extensive application in biomanufacturing (Chia and Wu, 2015) and 
pharmaceuticals (Alomari et al., 2015; Trenfield et al., 2018). The importance and relevance 
of 3D printing technologies for pharmaceutical applications have been extensively discussed 
elsewhere (Alhnan et al., 2016; Goole and Amighi, 2016; Palo et al., 2017; Zema et al., 2017) 
as an enabling technology to produce patient-tailored medicines (Pietrzak et al., 2015), to 
engineer drug release profiles from a dosage form (Fina et al., 2017; Fina et al., 2018; 
Goyanes et al., 2015d; Martinez et al., 2017; Wang et al., 2016) and to deliver multiple drugs 
(Khaled et al., 2015b; Khaled et al., 2015a). 
Fused deposition modelling (FDM) is the most commonly evaluated 3D printing technique in 
the pharmaceutical sciences owing to the use of relatively simpler and less-expensive 
equipment, diverse choice of excipients and ease of producing dosage forms, even with 
complex geometries, which have good patient acceptability (Goyanes et al., 2015c; Goyanes 
et al., 2017b; Schiele et al., 2013). The FDM process involves heating and extruding a drug 
loaded polymer strand (prepared beforehand by hot melt extrusion) through a nozzle tip 
followed by solidification onto a build plate into the desired geometry. One potential issue 
with this type of printing, therefore, is the high temperature the drugs might be exposed to 
during material extrusion and printing (Goyanes et al., 2015a; Goyanes et al., 2016a). In a 
previous study we reported that thermal degradation of 4-aminosalicylic acid during FDM 
printing reached 50%, emphasising the need for lowering the processing temperatures for 
thermally labile drugs (Goyanes et al., 2015a). 
The majority of the existing literature on pharmaceutical applications of FDM involves 
printing temperatures in the range of 150-230
o
C, primarily using polyvinyl alcohol (PVA), 
polylactic acid (PLA), hydroxypropyl cellulose (HPC), other cellulose derivatives and 
various grades of Eudragit polymers (RL, RS and E), since these polymers extrude and print 
well (Alhijjaj et al., 2016; Genina et al., 2017; Gioumouxouzis et al., 2017; Goyanes et al., 
2014; Goyanes et al., 2015b; Goyanes et al., 2018; Goyanes et al., 2017a; Goyanes et al., 
2016b; Goyanes et al., 2015c; Melocchi et al., 2015; Melocchi et al., 2016; Muwaffak et al., 
2017; Okwuosa et al., 2017; Pietrzak et al., 2015; Sadia et al., 2016; Skowyra et al., 2015; 
Solanki et al., 2018; Zhang et al., 2017a; Zhang et al., 2017b). However, most of these 
polymers, excluding Eudragit E and HPC, are not well suited for formulation of immediate 
  
release dosage forms, which account for approximately 70% of oral dosage formulations 
(Okwuosa et al., 2016). There are limited studies investigating immediate release 3D printed 
formulations, using PVP and Eudragit EPO, that print at relatively lower temperatures in the 
range of 110-135 
o
C (Okwuosa et al., 2016; Sadia et al., 2016). There is therefore a need to 
develop polymer filaments that (i) extrude and print at lower temperatures so as to enable 3D 
printing of thermolabile drugs and (ii) that are  suitable for immediate release formulations.  
Reports on the use of Kollidon VA64 and Kollidon 12PF in association with the  plasticizer - 
PEG 1500 on the suitability of polymers for hot melt extrusion throws light on these 
polymer-plasticizer combinations, as potential candidates for exploring possible filament 
compositions that could be printed at significantly lower temperatures (Karl et al., 2010). 
Kollidon VA64 is a water soluble vinylpyrollidone-vinyl acetate copolymer, widely used in 
pharmaceutical formulations as a direct compression, film-forming and taste-masking 
excipient and is known for its suitability in hot-melt extrusion processes. Kollidon 12PF is a 
low molecular grade polyvinylpyrrolidone commonly used as a solubilising agent and 
crystallization inhibitor. 
A drug that could benefit from advances in lower printing temperatures is ramipril, an 
angiotensin converting enzyme (ACE) inhibitor antihypertensive agent, normally used in 
combination with other drugs in the treatment of multitude of cardiovascular indications. 
Ramipril has a melting point of 109 °C and requires dose flexibility. It is available in fixed 
dosage strengths, ranging between 1.25 mg and 20 mg with an initial dose of 1.25 or 2.5 mg, 
and it needs adjustment depending on blood potassium levels and concurrent administration 
of diuretics (Warner and Perry, 2002).  
The objective of the present work was to explore the use of Kollidon VA64 and Kollidon 
12PF as suitable excipients to prepare immediate release formulations lowering the printing 
temperature of the FDM 3D printing process in order to accommodate thermolabile and low-
melting temperature drugs. Printlets (3D printed tablets) incorporating therapeutically 
relevant dose of ramipril (selected as a model drug) were prepared by FDM printing. 
Moreover, a secondary aim of the study was to apply this new knowledge to the printing of 4-
aminosalicylic acid (4-ASA), a drug which we have shown previously to undergo 
degradation during standard FDM printing conditions (Goyanes et al., 2015a). 
  
2. Material and Methods 
Ramipril (RMP) was purchased from Baoji Guokang Bio Technology Co Ltd (Baoji, China). 
Kollidon VA64 (vinylpyrrolidone-vinyl acetate copolymers) and Kollidon 12PF 
(polyvinylpyrrolidone) were obtained from BASF (Germany), PEG 1500 and magnesium 
carbonate were purchased from Sigma Aldrich (UK), Mannitol was purchased from Alfa 
Aesar (UK), formic acid and analytical grades of acetonitrile and methanol, and 4-
aminosalicylic acid (4-ASA) were purchased from VWR International Ltd., (UK). 
2.1. Preparation of drug-loaded ramipril filaments  
Kollidon VA 64, PEG 1500, mannitol, ramipril and magnesium carbonate (65%, 20%, 10%, 
3% and 2% w/w respectively) were manually mixed using a mortar and pestle (Table 1). The 
mixture was then extruded using a single-screw extruder (Noztek Pro filament extruder, 
NozteK, UK) at 70 °C through a nozzle with diameter 1.3 mm at screw speed of 15 rpm. The 
resulting filament was stored in a vacuum desiccator before printing. Ramipril loading in the 
filaments was determined by HPLC analysis. Filaments were also formulated by replacing 
50% and 40% of Kollidon VA64 from the above formulation with Kollidon 12PF (Table 1). 
 
2.2. 3D printing of ramipril dosage forms 
Dosage forms were fabricated with the drug-loaded filament using a standard fused-
deposition modelling 3D printer, MakerBot Replicator 2X Desktop (MakerBot Inc., USA). 
The template used to print the dosage form was designed with AutoCAD 2014 (Autodesk 
Inc., USA) and exported as a stereolithography (.stl) file into MakerWare v. 2.4.1 (MakerBot 
Inc., USA). The selected geometry of the dosage forms was a flat faced cylindrical tablet with 
dimensions, X = 10 mm, Y = 10 mm and Z = 3.6 mm. The infill percentage was 100% in 
order to produce solid dosage forms of high density and other printer settings were as 
follows: standard resolution with the raft option deactivated and an extrusion temperature of 
90 °C, speed while extruding (90 mm/s), speed while traveling (150mm/s), number of shells 





The physical dimensions of the printlets were measured using a digital Vernier caliper. 
Pictures of the devices were taken with a Nikon Coolpix S6150 with the macro option of the 
menu. 
2.4. Determination of the mechanical properties of the printlets  
The printlet breaking force of 6 printlets of each type was measured using a traditional tablet 
hardness tester TBH 200 (Erweka GmbH, Heusenstamm, Germany), whereby an increasing 
force is applied perpendicular to the tablet axis to opposite sides of a tablet until the printlet 
fractures. 
2.5. X-ray Powder Diffraction (XRPD) 
X-ray powder diffraction data were obtained using Cu-Kα (λ = 1.5418 Å) radiation with a 
Philips PANalytical X’Pert MPD Pro diffractometer (with PW3064 sample spinner and 
PANalytical Data Collector) operating at 40 kV. X-ray measurements were collected over a 
2θ range of 5–40° with a step size of 0.007° and scan step time of 60s. The resulting 
diffractograms were analysed using PANalytical High Score plus against the standard 
references from the Cambridge structural database. 
2.6. Thermal Analysis 
Differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) were used to 
characterise the melting point and degradation profile of the drug. DSC measurements were 
performed with a Q2000 DSC (TA Instruments, Waters, LLC, U.S.A.) at a heating rate of 10 
°C/min. Calibration for cell constant and enthalpy was performed with indium (Tm = 156.6 
°C, ΔHf = 28.71 J/g) according to the manufacturer instructions. Nitrogen was used as a 
purge gas with a flow rate of 50 mL/min for all the experiments. Data were collected with TA 
Advantage software for Q series (version 2.8.394), and analysed using TA Instruments 
Universal Analysis 2000. Melting temperature is reported as extrapolated onset unless 
otherwise stated. TA aluminium pans and lids (Tzero) were used with an average sample 
mass of 8−10 mg. For TGA analysis, samples were heated at 10 °C/min in open aluminium 
pans with a Discovery TGA (TA Instruments, Waters, LLC, U.S.A.). Nitrogen was used as a 
purge gas with a flow rate of 25 mL/min. Data collection and analysis were performed using 
TA Instruments Trios software and percent mass loss or onset temperature were calculated 
  
2.7. Determination of Drug Loading 
A printlet or a section of drug-loaded strand (approximately 1g) was placed in a volumetric 
flask with deionized water (1 L) under magnetic stirring until complete dissolution (n = 3). 
Samples of the solutions were then filtered through 0.45 μm filter (Millipore Ltd., Ireland) 
and the concentration of drug determined with HPLC (Hewlett-Packard 1050 Series HPLC 
system, Agilent Technologies, U.K.).  
The validated high performance liquid chromatographic assay entailed, injecting 5 μL 
samples for analysis using a mobile phase, consisting of isocratic system of aqueous phase 
(10%) composed of 0.1% formic acid and organic phase (90%) composed of methanol and 
acetonitrile (15:85) pumped at a flow rate of 1mL/min, through a Luna 5 μm C18 column, 
150 × 4.6 mm (Phenomenex, U.K.) maintained at 40 °C. The eluent was screened at a 
wavelength of 210nm. The assay method for ramipril was proven to be discriminatory for the 
impurity rampiril diketopiperazine (impurity D), anticipated inactive degradant of ramipril. 
Impurity D was prepared as per the method given by (Amjad Anwwari, 2008). Retention 
times of ramipril and the impurity D were found to be 2.4 and 6.1 min respectively. All 
measurements were made in duplicate. 
 
2.8.Dissolution testing 
Dissolution profiles were obtained using a USP-II apparatus (Model PTWS, Pharmatest, 
Germany). In each assay, the printlets were placed at the bottom of the vessel in 0.1N HCl pH 
1.2, (750 mL) under constant paddle stirring (50 rpm) at 37 °C. During the dissolution test, 
samples of ramipril were automatically removed and filtered through 10 µm filters and drug 
concentration was determined using an in-line UV spectrophotometer (Cecil 2020, Cecil 
Instruments Ltd., Cambridge, UK) operated at the wavelength of maximum absorbance of the 
drug in 0.1N HCl (210 nm). Data were processed using Icalis software (Icalis Data Systems 
Ltd., Berkshire, UK). Tests were conducted in triplicate under sink conditions. Data are 
reported throughout as mean ± standard deviation. 
2.9. Raman Spectroscopy 
Raman spectroscopy was carried out using a LabRAM HR Evolution (HORIBA UK Ltd.) in 
a backscatter configuration with 532 nm excitation (laser power 499 mW), and an acquisition 
time of 10 s for 3 accumulations. Spectra were collected using a 50X objective at a 4 cm
−1
 
resolution, over scan ranges of 50 to 3400 cm
-1
 using 600 gr/mm grating. For the spectra 
collected in z-axis, 100X objective was used with a step size of 1 µm. Variable temperature 
  
experiments were conducted using a hot stage associated with the spectrometer. Samples 
were heated at 10 °C/min and held for 5 min at specific temperature while spectra were 
collected. 
2.10.  Solid state nuclear magnetic resonance (SSNMR) spectroscopy 
Solid-state NMR data were acquired on a Bruker Avance III HD wide bore NMR 
spectrometer operating at a static magnetic field strength of B0 = 9.4 T.  Powdered or granular 
samples of Ramipril, Ramipril diketopiperazine, extruded filament, and a physical mixture of 
the compounds comprising the extruded filament were packed into 4 mm o.d. zirconia rotors 
with either Kel-F or zirconia caps.  Carbon-13 NMR spectra were acquired under magic 
angle spinning (MAS) conditions using a Bruker 4 mm triple resonance (X/Y/
1
H) MAS probe 




H Larmor frequencies 
of ν0 = 100.6 and 400.1 MHz, respectively, and processed using TopSpin version 3.5pl7.  
NMR spectra were acquired at temperatures between 20 and 90 °C. The sample temperature 
in variable temperature NMR experiments was controlled with a BVTB 3500 temperature 
control unit operated via the TopSpin software.  The heating rate was limited to a maximum 
of 5 °C/min. 
Carbon-13 NMR spectra were collected using a cross polarization (CP) pulse sequence with 
total suppression of spinning sidebands (TOSS) (Antzutkin, 1999; Song et al., 1993). Proton 
90 degree pulses were 3 μs in length, and 
13
C 90 and 180 degree pulses were 4 and 8 μs in 
length, respectively.  Samples were spun at MAS rates of 6 or 12 kHz.  Proton decoupling at 
a frequency of 83 kHz was carried out using the SPINAL64 (Fung et al., 2000) decoupling 
sequence. Proton T1 values were determined using the saturation recovery pulse sequence and 
recycle delays were an optimized 1.3*T1 for each sample at each temperature except where 
short recycle delays were prohibited by the duty cycle. Recycle delays varied from 3.5 to 5 s 
for Ramipril, 3.5 s for Ramipril diketopiperazine, and were 10 s for the filament and the 
physical mixture of compounds. Contact times in CP experiments were optimized for bulk 
crystalline Ramipril and were 2 ms. The number of transients obtained for the 
13
C NMR 
spectra of Ramipril and Ramipril diketopiperazine ranged from 243 to 1944; 7290 transients 
were averaged for the 
13
C NMR spectra of the filament and physical mixture of compounds.  
Carbon-13 chemical shift values were referenced to TMS at δ = 0 ppm by adjusting the field 
such that the methylene peak in the 
13
C NMR spectrum of solid adamantane resonated at δiso 
= 38.48 ppm (Morcombe and Zilm, 2003). For all 
13
C NMR spectra, 10 Hz of line 
broadening was applied before processing. 
  
Sample temperatures under MAS conditions were calibrated using 
207
Pb NMR spectra of 
solid powdered lead (II) nitrate (Bielecki and Burum, 1995; Takahashi et al., 1999). The 
temperature at ambient conditions was determined using a sample of neat methanol 
(Ammann et al., 1982). Lead-207 NMR data were acquired using single-pulse experiments 
with a 4 μs 90 degree pulse at a Larmor frequency of 83.4 MHz. The recycle delay and 
number of transients in 
207
Pb NMR spectra were 60 s and 16 transients, respectively. 
Plots of NMR spectra were prepared for publication with DMFit (Massiot et al., 2002). 
 
2.11.  3D printing of 4-aminosalicylic acid (4-ASA) printlets and HPLC determination 
A filament of Kollidon VA 64, PEG 1500, mannitol, 4-ASA and magnesium carbonate (65%, 
20%, 10%, 3% and 2% w/w respectively) was prepared as in section 2.1. Printlets of 4-ASA 
prepared with Kollidon VA 64 filament were fabricated as in section 2.2 under the same 
conditions.  
4-ASA loading in the printlets was determined by HPLC analysis as reported in section 2.7.  
For 4-ASA, the HPLC method involved injecting 10 μL samples for analysis using a mobile 
phase, consisting of isocratic system of aqueous phase (76%) composed of 0.1% 
orthophosphoric acid and organic phase (24%) composed of acetonitrile pumped at a flow 
rate of 1mL/min through a Discovery HSF5 column (4.6 × 150 mm) maintained at 40 °C. 
The eluent was screened at a wavelength of 303nm, all measurements were made in 
duplicate. 
 
3. Results and discussion 
 
Ramipril printlets were successfully printed at 90 
o
C by FDM 3D  for all the formulations 
listed in the Table 1 (Figure 1). The printlets produced were white and showed good 
uniformity in physical dimensions, with a mean thickness of 3.62 ± 0.05 mm, diameter of 
10.54 ± 0.04 mm, and weight of 294.5 ± 3 mg.  
All the formulations showed appropriate properties for handling and were mechanically 
strong. The printlet breaking force data show values close to 485 N that represent the 
  
maximum value measurable by the tablet hardness tester. These values are comparable to 
those previously reported from printlets prepared using polyvinyl alcohol (PVA) (Goyanes et 
al., 2015a). 
The immediate release polymers Kollidon VA 64 and Kollidon 12PF were found to be viable 
excipients for printing at temperatures below 100 °C. Initially ramipril loaded filaments were 
produced using Kollidon VA64 alone as the polymer without any Kollidon 12PF, in 
combination with PEG 1500 as a primary plasticizer, mannitol, and  magnesium carbonate as 
a stabilising agent. Mannitol was added as a secondary plasticizer to produce filaments with 
sufficient flexibility for printing and additionally for its pore former capacity, since mannitol 
has been also reported to work as a channelling agent in 3D printed formulations (Beck et al., 
2017). Magnesium carbonate is a pharmaceutically accepted excipient, which has been 
reported to have a stabilizing effect on ACE inhibitors in a formulation by providing an 
alkaline environment that protects the active ingredient from oxidation, hydrolysis and 
cyclization (Harris et al., 1988), and is also known for its application in high temperature 
insulating compositions (Farrar, 1994). Numerous formulations were tested with varying 
polymer and plasticizer combinations (data no shown) in order to achieve filaments that 
could be produced at lower temperatures and that also had a good balance between flexibility 
and tensile strength so as to avoid collapsing and breaking during printing. The first selected 
formulation (VA64 from Table 1) was processed by hot melt extrusion at 75 °C to obtain the 
filament, which was used to print the cylindrical printlets (Figure 1) at 90 °C. A die with a 
diameter of 1.3 mm was used for extruding the 1.75 mm diameter filaments required for 
printing, due to the polymer expansion after leaving the nozzle of the extruder.  
It is of the utmost importance to demonstrate the stability of the ramipril during extrusion and 
printing steps, considering its susceptibility to a range of factors such as mechanical stress, 
heat, moisture and excipients (Shafiq and Shakeel, 2008). DSC and TGA data used to 
determine the melting point and degradation profile of the drug indicates that ramipril has a 
melting point of 109 °C (Figure 2), the drug with the lowest melting temperature printed by 
FDM so far to the authors’ knowledge, which highlights the need for printing the drug at 
lower temperatures. Although the loss mass in the TGA is not observed until higher 
temperatures (130 °C), below the melting point the drug is not stable and transforms in 
ramipril diketopiperazine (impurity D) (Amjad Anwwari, 2008). 
  
Chemical integrity of the drug in the final printlets and drug-loaded filaments was analysed 
using HPLC; the drug loading of the filaments was 3.03 wt% ± 0.04 (theoretical loading- 3 
wt%) and in the printlets was 8.83 ± 0.14 mg (theoretical amount- 8.9 mg), indicating no drug 
degradation. The stability of the drug over the processing temperature range was further 
confirmed using variable temperature Raman and SSNMR studies. Ramipril was analysed 
using a Raman spectrometer equipped with a hot stage microscope over a temperature range 
between 20 °C and 109 °C (melting point). The sample was analysed for any degradation by 
evaluating the Raman spectra collected, at room temperature, at 70 °C, the extrusion 
temperature and at 90°C, the printing temperature, Figure 3. 
The drug is exposed to a specific temperature for a longer time during the extrusion than 
during the printing process. Taking this into consideration ramipril was held at 70 °C for 30 
min and at 90 °C for 5min on a hot stage microscope, emulating longer exposure times to the 
temperatures during the extrusion and printing steps. It is evident from the micrographs 
(Figure 4) and the spectral data (Figure 3) that ramipril did not undergo any degradation 
under these temperatures. Hence, ramipril is expected to be stable in the formulations, which 
are composed of 97% excipients, thereby exhibiting an additional insulating effect on the 
drug. 
The significance of printing ramipril at lower temperatures is further explained by studying 
the behaviour of ramipril melt during the cooling cycle. Ramipril was allowed to completely 
melt by heating the hot-stage to 109 °C and spectra were collected at different intervals 
during the cooling cycle of the melt. It was observed that the Raman spectra of the cooled 
material are different from that of crystalline ramipril. Splitting of the peak corresponding to 
the C = O functional group (in conjugation with the primary amide) observed in the 
frequency region of 1635-1665 cm
-1
 and the absence of the peak corresponding to the O-H 
functional group in the frequency region of 3200-3400 cm
-1
 were identified as the 
predominant differences in the cooled melt and ramipril as received (Figure 5). This can be 
explained by the possibility of degradation of ramipril to its impurity D during melting. 
Studies suggest that rampiril diketopiperazine (impurity D) can be synthesised by heating 
ramipril to 120 °C for up to 6 to 8 hr (Amjad Anwwari, 2008) and the Raman spectra of 
impurity D synthesised by this method (Figure 7) was similar to that of the cooled melt of the 
ramipril (Figure 6).  The absence of the carboxylic hydroxyl group and the presence of di-
ketone (primary amide) functionality in the impurity D, further corroborate the differences 
observed in the Raman spectra of the ramipril collected, before and after melting. This 
  
emphasises the need for processing ramipril at lower temperatures. These results also show 
the potential of Raman spectroscopy as an in-line tool to monitor process induced transitions 
even at low drug concentration (3% in this case). In line monitoring would require pre 
formulation experiments to prepare calibration curves and the application of chemometrics to 
analyse the Raman data, however demonstrations with 2D printed formulations have been 
already reported using different drugs (Edinger et al., 2017). 
Variable temperature SSNMR was used to support the results obtained from Raman 
spectroscopy. The SSNMR spectra of ramipril collected at temperatures used for extrusion 
and printing, were similar to that of the ramipril at room temperature except the broadening 
of the peaks observed in the chemical shift region 120-140 ppm (Figure 8), which possibly 
could be due to the molecular vibrations at higher temperatures. The spectrum collected after 
cooling the sample back to the room temperature (Figure 8) further corroborates the stable 
nature of ramipril over processing temperature range. 
XRPD and SSNMR were used to examine the solid state of the active ingredient in the final 
formulations. X-ray diffractograms of the pure components of the formulation were examined 
and the peaks corresponding to 2θ°- 7.6 and 8.11, were identified as the drug peaks without 
any interference from the excipient (Figure 9). The physical mixture of the formulation shows 
tiny peaks in this region indicating the crystalline nature of the drug but the powdered printlet 
does not show any peaks suggesting either the amorphous nature of the drug in the final 
formulation or the percentage of the drug is beyond the limit detection of the characterisation 
technique. Similar results were observed with SSNMR (Figure 10) where the physical 
mixture showed the presence of crystalline ramipril but the powdered printlet did not show 
any such signs, which again could possibly due to the amorphous nature of ramipril. 
Having confirmed the applicability of Kollidon VA64 for FDM printing at lower 
temperature, additional filaments were also produced by replacing Kollidon VA64 entirely 
with Kollidon 12PF, while maintaining the rest of the formulation components constant. The 
extrusion process of this formulation was much smoother and efficient with an extrusion 
temperature of 65 °C, which was lower than that used for Kollidon VA64. However these 
filaments were very brittle and not suitable for the subsequent printing steps. This could 
possibly be due to the lower molecular weight  of the Kollidon 12PF which does not facilitate 
long range interlinking of the polymer chains, essential for the tensile strength of the 
filament. Taking into account the flexibility in filaments and ease of extrusion achieved using 
  
Kollidon VA64 and Kollidon 12PF respectively, filaments were produced using formulations 
where Kollidon VA64 was partly replaced by Kollidon 12PF (VA64:12PF in the ratios 3:2 
and 1:1 as shown in Table 1). This resulted in production of filaments at a temperature of 65 
°C,which were suitable for printing at 90 °C. XRPD and HPLC results of these formulations 
were similar to that of the formulation VA64, showing drug stability during the printing 
process (data not shown).  
Dissolution studies of all three formulations were performed in 0.1N HCl, simulating gastric 
conditions, as they were formulated with the objective of producing immediate release 
dosage forms. As the polymers themselves are water soluble and with the low molecular 
weight water soluble components in the formulations acting as a pore formers, 100% drug 
release was achieved within 20 to 30 min (Figure 11). Formulations containing Kollidon 
12PF were observed to have faster drug release when compared to the Kollidon VA64 alone. 
This pattern is explained considering the extensive application of Kollidon 12PF as a 
solubility enhancer in pharmaceutical applications. Based on these observations, the 
mechanism of drug release from these Kollidon based FDM products could be explained 
chiefly by erosion. 
A previous study showed that 4-ASA when printed at temperatures generally used for FDM 
was degraded to approximately half of its initial dose (Goyanes et al., 2015a). To emphasise 
the significance of lowering the printing temperature in FDM and as a probe that the selection 
of the right formulation composition could avoid degradation while printing, 4-ASA printlets 
were produced based on the formulation Kollidon VA64. The 4-ASA loaded Kollidon VA64 
filaments were extruded at 75 °C and printed at 90°C. The evaluation of the drug content 
using HPLC showed a drug loading of the filaments of 2.91 wt% ± 0.02 (theoretical loading- 
3 wt%) and the amount of drug in the final printlets was 9.28 ± 0.06 mg (theoretical amount- 
9.01 mg). These results suggest that drug did not undergo any degradation either during 
extrusion or printing, thereby validating the significance of selecting polymers to print at 
lower temperatures. 
Conclusion 
Manufacture of printlets of ramipril, a drug with a low melting point (109°C), has been 
successfully demonstrated by FDM at 90 °C. The polymer Kollidon VA64 alone or in 
combination with Kollidon 12PF produced immediate release printlets by FDM printing with 
  
no signs of drug degradation. The mixed polymer printlets showed slightly faster drug release  
compared with those formulated with Kollidon VA64 alone. The applicability of these 
formulations to prepare low-melting temperature and thermolabile medicines by FDM 
printing has been demonstrated also with the drug 4-ASA, which in a previous study showed 
that when printed at temperatures generally used for FDM printing was degraded to 
approximately half its initial dose. This work demonstrates that the selection and use of new 
excipients can overcome one of the major disadvantages in FDM printing, drug degradation 
due to thermal heating, making this technology suitable for drugs with lower melting 
temperatures.  
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Figure 1. Pictures of ramipril printlets, from left to right: VA64, VA64:12PF (3:2) and 
VA64:PF12 (1:1) 
Figure 2. DSC and TGA plots of ramipril 
Figure 3. Raman spectra of ramipril collected at different temperatures (a) at room 
temperature, (b) at 70 °C after 30 min, (c) at 90 °C after 5min,  (d) at 105 °C, (e) at 107 °C, 
(f) at 108 °C, corresponding to images in the Figure 4. 
Figure 4. Optical micrographs of ramipril from hot-stage Raman spectrometer collected at 
different temperatures (a) at room temperature, (b) at 70°C after 30 min, (c) at 90°C after 
5min, (d) at 105°C, (e) at 107°C, (f) at 108°C. 
Figure 5. Optical micrographs of ramipril from hot-stage Raman spectrometer collected at 
different time intervals post-melting (a) after 5 min, (b) after 60 min, (c) after 180 min. 
Figure 6. Raman spectra of ramipril collected at different time intervals post-melting (a) after 
5 min, (b) after 60 min, (c) after 180 min, corresponding to images in the Figure 5. 
Figure 7. Schematic representation of synthesis of impurity D from ramipril, with marked 
functional groups, responsible for the differences in the Raman spectra. 
Figure 8. Experimental 
13
C MAS NMR spectra of bulk crystalline Ramipril under variable 
temperature conditions and of Ramipril diketopiperazine (DKP) at ambient conditions. 
Spectra were acquired at B
0
 = 9.4 T using the CP/TOSS pulse sequence with 
1
H decoupling 
and from top to bottom consist of 1944, 243, 486, 486, and 1944 transients. The MAS 
frequency was 6 kHz for Ramipril and 12 kHz for Ramipril diketopiperazine. Temperatures 
shown are peak sample temperatures. 
Figure 9. X-ray powder diffractograms of pure components, physical mixture before printing 
and powdered printlet of the three formulations. 
Figure 10. Experimental 
13
C MAS NMR spectra of Ramipril, Ramipril diketopiperazine 
(DKP), extruded filament, and a physical mixture of the compounds comprising the filament.  
Spectra were acquired at B0 = 9.4 T using the CP/TOSS pulse sequence with 1H decoupling 
  
and consist of 4860, 1944, 7294, and 7294 transients, respectively. The MAS frequency was 
12 kHz for all samples.    













































































VA64 3 2 10 20 65 - 70 90 
VA64:12PF 
(3:2) 
3 2 10 20 39 26 65 90 
VA64:12PF 
(1:1) 
3 2 10 20 32.5 32.5 65 90 
 
 
